Shoulder Innovations, Inc. (SI)
NYSE:SI
Want to see SI full AI Analyst Report?
SI Stock Chart & Stats
$14.54
<$0.01(0.07%)
At close: 4:00 PM EDT
$14.54
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$10.92 - $17.94
Previous Close$15.29
Volume91.20K
Average Volume (3M)130.13K
Market Cap
$308.58M
Enterprise Value$316.67M
Total Cash (Recent Filing)$108.54M
Total Debt (Recent Filing)$15.01M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Sep 15, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding20,738,226
10 Day Avg. Volume53,279
30 Day Avg. Volume130,135
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)7.23
Price to Sales (P/S)23.67
P/FCF Ratio-31.09
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue5.88
Enterprise Value/Gross Profit7.65
Enterprise Value/Ebitda-7.27
Forecast
1Y Price Target
$21.50Price Target Upside47.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$64.12M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsSustained high revenue growth alongside ~77% gross margins demonstrates attractive unit economics and scalable product economics. Over the next 2–6 months this structural combination should enable operating leverage as fixed costs are spread across rising volumes, supporting margin improvement potential if SG&A growth moderates.
Product & Technology ExpansionRegulatory clearance and full commercial launch of a broadened humeral stem line, new product releases, an expanding clinical registry and a progressing robotic partnership materially expand the company’s addressable procedures and clinical credibility. These durable product milestones strengthen differentiation and support longer-term surgeon adoption and market penetration.
Balance Sheet Flexibility & Cash RunwayA sizable cash balance combined with low leverage gives the company a multi-month runway to fund commercialization, inventory builds and R&D investments without immediate financing. This structural cushion reduces short-term funding risk and allows execution on go-to-market and regulatory milestones while management works toward cash-flow breakeven.
Bears Say
Accelerating Cash BurnMaterial negative operating and free cash flow and an accelerating burn rate signal the business is not self-funding. Over the next several months this structural cash outflow increases dependency on existing liquidity or capital markets, raising execution risk if revenue or funding assumptions weaken before break-even is reached.
Widening Operating And Net LossesRising net and adjusted EBITDA losses reflect operating expense expansion that is outpacing revenue growth. Persistently negative returns impair the company’s ability to compound shareholder value and extend the timeline to profitability, leaving underlying economics reliant on continued robust adoption and eventual cost control.
High SG&A And R&D Investment PressureElevated and rising SG&A and R&D spend are necessary to scale commercialization and product development but are currently outpacing revenue contribution. Structurally higher operating expenses increase the break-even hurdle and make margins sensitive to slower-than-expected adoption or ASP/mix variability over the medium term.
Shoulder Innovations, Inc. News
SI FAQ
What was Shoulder Innovations, Inc.’s price range in the past 12 months?
Shoulder Innovations, Inc. lowest stock price was $10.92 and its highest was $17.94 in the past 12 months.
What is Shoulder Innovations, Inc.’s market cap?
Shoulder Innovations, Inc.’s market cap is $308.58M.
When is Shoulder Innovations, Inc.’s upcoming earnings report date?
Shoulder Innovations, Inc.’s upcoming earnings report date is Sep 15, 2026 which is in 116 days.
How were Shoulder Innovations, Inc.’s earnings last quarter?
Shoulder Innovations, Inc. released its earnings results on May 13, 2026. The company reported -$0.41 earnings per share for the quarter, the consensus estimate of -$0.41 by $0.
Is Shoulder Innovations, Inc. overvalued?
According to Wall Street analysts Shoulder Innovations, Inc.’s price is currently Undervalued.
Does Shoulder Innovations, Inc. pay dividends?
Shoulder Innovations, Inc. does not currently pay dividends.
What is Shoulder Innovations, Inc.’s EPS estimate?
Shoulder Innovations, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Shoulder Innovations, Inc. have?
Shoulder Innovations, Inc. has 20,738,226 shares outstanding.
What happened to Shoulder Innovations, Inc.’s price movement after its last earnings report?
Shoulder Innovations, Inc. reported an EPS of -$0.41 in its last earnings report, expectations of -$0.41. Following the earnings report the stock price went up 15.225%.
Which hedge fund is a major shareholder of Shoulder Innovations, Inc.?
Currently, no hedge funds are holding shares in SI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shoulder Innovations, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (47.87% Upside)
$21.50 (47.87% Upside)
Hedge Fund Trend
Decreased
By 482.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $78.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-89.55%
Trailing 12-Months
Asset Growth
178.77%
Trailing 12-Months
Company Description
Shoulder Innovations, Inc.
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
SI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operating and commercial momentum: sizable revenue and volume growth, improving gross margins, accelerating surgeon adoption and meaningful product and technology milestones (I-135 full launch, N22 limited release, >500 patients in registry, and a progressing robotic partnership). These positives were offset by increased operating expenses and larger net and adjusted EBITDA losses as the company invests to scale, a Q1 cash burn driven by inventory and working capital, and some seasonality and ASP/mix variability risk embedded in the updated guidance. Overall, management expressed high conviction in the trajectory and raised full-year guidance while noting near-term investment-related impacts.View all SI earnings summariesSI Stock 12 Month Forecast
Average Price Target
$21.50
▲(47.87% Upside)
Technical Analysis
Ownership Overview
58.72% Insiders
6.08% Mutual Funds
7.87% Other Institutional Investors
23.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---